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Abstract
The amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) reverses dopamine and serotonin
transporters to produce efflux of dopamine and serotonin, respectively, in regions of the brain that have been implicated in
reward. However, the role of serotonin/dopamine interactions in the behavioral effects of MDMA remains unclear. We
previously showed that MDMA-induced locomotion, serotonin and dopamine release are 5-HT2B receptor-dependent. The
aim of the present study was to determine the contribution of serotonin and 5-HT2B receptors to the reinforcing properties
of MDMA. We show here that 5-HT2B
2/2 mice do not exhibit behavioral sensitization or conditioned place preference
following MDMA (10 mg/kg) injections. In addition, MDMA-induced reinstatement of conditioned place preference after
extinction and locomotor sensitization development are each abolished by a 5-HT2B receptor antagonist (RS127445) in wild
type mice. Accordingly, MDMA-induced dopamine D1 receptor-dependent phosphorylation of extracellular regulated
kinase in nucleus accumbens is abolished in mice lacking functional 5-HT2B receptors. Nevertheless, high doses (30 mg/kg)
of MDMA induce dopamine-dependent but serotonin and 5-HT2B receptor-independent behavioral effects. These results
underpin the importance of 5-HT2B receptors in the reinforcing properties of MDMA and illustrate the importance of dose-
dependent effects of MDMA on serotonin/dopamine interactions.
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Introduction
Activation of the mesolimbic dopaminergic system, which
consists of projections from the midbrain ventral tegmental area
(VTA) to forebrain regions, including the nucleus accumbens
(NAcc), is critical for the psychostimulant and reinforcing effects of
drugs of abuse [1]. Dopamine (DA) increase in the NAcc plays a
critical role in reward and drug dependence and is a common
response generated by all drugs of abuse [1]. On the other hand,
emerging data support a role of serotonin (5-HT) in the rewarding
effects of psychostimulants [2]. Serotonergic neurons from the
dorsal raphe ´ nucleus project to the VTA and the NAcc and impact
dopaminergic neurotransmission [2,3]. Thus, regulation of
mesolimbic DA activity by 5-HT and its receptors plays an
important role in the reinforcing effects of drugs of abuse [4],
including the ‘club drug’ MDMA [5–8].
MDMA binds to and reverses the dopamine transporter (DAT)
and the serotonin transporter (SERT) to produce carrier-mediated
efflux of DA and 5-HT, respectively [9]. However, when access to
SERT is blocked by selective serotonin reuptake inhibitors (SSRI),
MDMA-evoked DA efflux in the NAcc is reduced [10–12]. In
humans, relevant studies have shown that most of MDMA’s effects
are also markedly reduced after administration of 5-HT receptor
antagonists or SSRIs, suggesting that these effects depend on
SERT-mediated enhancement of 5-HT transmission [13]. In
other words, MDMA-induced DA release in the NAcc is only
partially carrier (DAT) - mediated but also involves a SERT-
dependent 5-HT release.
Despite a widespread distribution in the central nervous system
(CNS) [14–17], 5-HT2B receptor function in the brain is mainly
unknown. However, 5-HT2B receptor mRNA and protein are
coexpressed in SERT-expressing primary neurons from mice
raphe ´ nuclei [18]. This study showed that 5-HT2B receptors
govern the overall 5-HT transport system by promoting
phosphorylation of SERT in these neurons [18]. Using reverse
transcription polymerase chain reaction (RT-PCR), we recently
confirmed that the 5-HT2B receptor mRNA is expressed in mouse
raphe ´ nucleus [19], as previously observed in rats by DNA
microarray and in situ hybridization [14]. Moreover, acute
pharmacological inhibition or genetic ablation of the 5-HT2B
receptor in mice completely abolishes MDMA (10 mg/kg)-
induced hyperlocomotion and 5-HT/DA release in NAcc and
VTA [19]. Indeed, functional pre-synaptic 5-HT2B receptors are
required for MDMA-induced SERT dependent 5-HT release
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7952in vivo and in vitro [19]. The absence of 5-HT and DA release in the
NAcc raises the question of the MDMA reinforcing effect in mice
lacking functional 5-HT2B receptors.
The main goal of the present study was to evaluate the role of
5-HT2B receptors in activation of mesolimbic dopaminergic system
and the reinforcing effects of MDMA. We first compared the
behavioral effect of MDMA (10 and 30 mg/kg) in 5-HT2B
2/2,
RS127445 (selective 5-HT2B receptor antagonist)-treated and WT
(wild type) mice using locomotor sensitization. NAcc microdialysis
studies were performed in awake WT, 5-HT2B
2/2 and RS127445-
treated WT mice to evaluate the effects of acute MDMA (30 mg/kg)
injection on DA and 5-HT extracellular levels. We then performed
conditioned place preference paradigms in WT, 5-HT2B
2/2 and
RS127445-treated WT mice to evaluate the role of 5-HT2B receptor
in the reinforcing effects effect of MDMA. Psychostimulants and
otherdrugsofabuse,includingMDMA,activate extracellularsignal-
regulated kinase (ERK) in the striatum, an essential component of a
signaling pathway involved in synaptic plasticity and long-term
effects of drugs of abuse. Thus, we quantified phosphorylated-ERK
(p-ERK) immunoreactive neurons in the NAcc of WT and
5-HT2B
2/2 mice after MDMA conditioning in the CPP paradigm.
Finally, using drd2-EGFP transgenic mice, we characterized–for the
first time– the populations of striatal dopaminergic neurons in which
MDMA activates the pERK signaling pathways in mice expressing
CPP.
Materials and Methods
Animals
5-HT2B
2/2 mice used in these experiments were made in a
pure 129Sv/PAS background. Wild type 129/SvPAS mice (8–10
week old) used as a control group were bred in-house. Swiss-
Webster male mice (10 week-old) carrying drd2-EGFP bacterial
artificial chromosome transgenes were generated by the Gene
Expression Nervous System Atlas program at Rockefeller
University (New York) [20]. Groups were composed of 50% male
and 50% female for each experiment.
Ethics Statement
Mice were kept under controlled environmental conditions
(22uC, 12 h alternate light-dark cycles, 50% humidity, food and
water ad libitum). The surgical procedures were performed under
deep anesthesia (pentobarbital 25 mg/g, xylazine 20 mg/g).
Behavioral tests and animal care were conducted in accordance
with the standard ethical guidelines (National Institutes of Health’s
‘‘Guide for the care and use of Laboratory animals’’, and the
European Communities Council European Communities Direc-
tive 86/609 EEC). All experiments involving mice were approved
by the Ile de France Regional Ethics Committee for Animal
Experiments.
Microdialysis
Anesthetized animals were placed in a stereotaxic frame (D.
Kopf, Tujunga, CA, USA) and a stainless-steel guide cannula
(CMA/12, CMA Microdialysis, North Chelmsford, MA, USA;
outer diameter 0.7 mm) was implanted in the NAcc. The cannula
was then secured to the skull with dental cement, and the skin was
sutured. Animals were kept in individual cages for a seven-day
recovery. The microdialysis experiment was performed using
awake mice. Dialysis probes were equipped with a Cuprophan
membrane (membrane length 1 mm and diameter 0.24 mm,
cutoff: 5,000 Da, Microdialysis AB, Sweden). According to
Franklin and Praxinos (1997), stereotaxic coordinates in mm were
for NAcc AP +1.2, ML +0.6, DV 24.2 both to bregma and dura
surface, respectively. Probes were perfused at a constant rate of
5 ml/min with artificial CSF containing 154.1 mM Cl-, 147 mM
Na+, 2.7 mM K+, 1 mM Mg2+, and 1.2 mM Ca2+, adjusted to
pH 7.4 with 2 mM sodium phosphate buffer in awake animals.
Dialysates were collected every 10 min. All measurements were
carried out 150 min after the beginning of perfusion, by which
time a steady state was achieved. Mice were injected with MDMA
(30 mg/kg; i.p) 35 minutes after the beginning of measurements.
Mice received a saline or RS127445 (0.5 mg/kg; i.p) injection
30 min before the MDMA injection. At the end of the experiment,
all brains were fixed in a 4% formaldehyde solution and serial
coronal slices were made on a microtome. Histological examina-
tion of cannula tip placement was subsequently made on 100 mm
safranine-stained coronal sections. Dialysate samples were injected
without any purification into an HPLC system that consists of a
pump linked to an automatic injector (Agilent 1100, Palo Alto,
CA, USA), a reverse-phase column (Zorbax SB C18, 3.5 lm,
150 ? 4.6 mm; Agilent Technologies, Palo Alto, CA, USA) and a
coulometric detector (Coulochem II; ESA Inc., Chelmsford, USA)
with a 5011 analytical cell to quantify DA or 5-HT. The first
electrode was fixed at -100 mV and the second electrode at
+300 mV. The gain of the detector was set at 50 nA. The signal
of the second electrode was connected to an HP Chemstation
for HPLC. The composition of the mobile phase was 50 mM
NaH2PO4, 0.1 mM Na2EDTA, 0.65 mM octyl sodium sulphate
and 14% (v/v) methanol, pH 3.5. The flow rate was set at
1 ml/min.
Locomotor Activity
Locomotor activity was measured in a circular corridor with
four infrared beams placed at every 90u (Imetronic, France).
Counts were incremented by consecutive interruption of two
adjacent beams (i.e., mice moving through one-quarter of the
corridor). Mice were injected with a saline solution and
individually placed in the activity box for 30 min during 3 days
consecutively for habituation before all locomotor experiments.
Locomotor Sensitization
We used two models of locomotor sensitization in this study, a
two-injection protocol [21] and a repeated drug injections protocol
(Fig. 1). Mice received a first injection of MDMA and the
locomotor activity was recorded for two hours (two-injection
protocol). Mice were then challenged seven days later with a
second injection of MDMA (test injection) and the locomotor
activity was recorded for two hours. For testing the role of 5-HT2B
receptors in the induction of sensitization, mice received a saline or
RS127445 (0.5 mg/kg) injection 30 min before the first MDMA
injection. For the repeated drug injections protocol, mice received
a daily injection of MDMA (10 mg/kg) during 5 days and the
locomotor activity was recorded during two hours. Mice were then
challenged 5 days later with a single injection (MDMA 10 mg/kg)
and locomotor activity was recorded during two hours.
CPP Acquisition
CPP experiment, consisting of three phases, was carried out
following a procedure biased in terms of initial spontaneous
preference [22]. CPP was assessed in a two-compartment
apparatus (Imetronic, Pessac, France) with different patterns on
floors and walls, separated by a central neutral area. During the
first phase or pre-conditioning (Pre-C) mice were given access to
both compartments of the apparatus for 30 min each day for four
days. On day four, the time spent by the animal in each
compartment was recorded for 30 min. In the second phase
(conditioning), animals were conditioned with MDMA or saline
5-HT2BR in Ecstasy Reward
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compartment respectively. Mice received only one pairing each
day. Animals conditioned with MDMA received an injection of
MDMA 10 min before confinement in the drug-paired compart-
ment for 30 min on days 5, 7, 9, and 11 and received physiological
saline 10 min before being confined to the vehicle-paired
compartment for 30 min on days 6, 8, 10, and 12; control
animals received an injection of physiological saline 10 min before
being confined for 30 min to each compartment alternatively.
During the third phase or post-conditioning (Post-C), on day 13,
the guillotine doors separating the two compartments were
removed and the time spent by the mice (untreated) in each
compartment was recorded during 30 min. The difference in
seconds between the time spent in the drug-paired compartment
in the Post-C test and that spent in the Pre-C test is a measure of
the degree of conditioning induced by the drug (Score). If this
difference is positive then the drug has induced a preference for
the drug-paired compartment, whereas the opposite indicates the
induction of an aversion.
Extinction
Control and MDMA-conditioned groups underwent an extinc-
tion session during which the animals were placed in the apparatus
(without guillotine doors separating the compartments) for 30 min
until the time spent in the drug-paired compartment for each
group conditioned with MDMA was similar to those of Pre-C (one
extinction session per day during 12 days). MDMA-treated
animals received the same number of extinction sessions,
independently of their individual scores, as the criterion of
extinction was a lack of significant difference with respect to
Pre-C values. Saline conditioned groups only performed one
extinction session to confirm the lack of CPP.
Reinstatement
The effects of a priming dose of MDMA were evaluated 48 h
after the confirmation of extinction. The tests of reinstatement
were the same as for Post-C (free ambulation for 30 min) except
that animals were tested 24 h after the administration of MDMA.
For testing the role of 5-HT2B receptors in the induction of
reinstatement, mice received saline or RS127445 (0.5 mg/kg)
30 min before the MDMA priming injection.
Tissue Preparation and Immunofluorescence
Twenty-four hours after CPP training, WT and 5-HT2B
2/2
mice were re-exposed to saline, MDMA 10 mg/kg or MDMA
Figure 1. Effect of 5-HT2B receptor inhibition on locomotor
activity and behavioral sensitization after MDMA injection.
Locomotor sensitization after MDMA two-injection protocol in
WT and 5-HT2B
2/2 mice (A–D): MDMA (10 mg/kg i.p.) increases
locomotor activity after the first injection (1
st) in WT mice but not in
5-HT2B
2/2 mice A) or RS127445-treated WT mice B). The stimulant
effect of a challenge dose of MDMA (10 mg/kg) 7 days later (2
nd) was
significantly enhanced compared to the first injection in WT mice, while
it had no effect in 5-HT2B
2/2 mice A) or RS127445 pre-treated WT mice
B). To evaluate the role of 5-HT2B receptors in the development of
locomotor sensitization, WT mice were treated with RS127445 30 min
before the first injection of MDMA. The increased responsiveness to the
challenge injection of MDMA in absence of RS127445 was totally
abolished C). MDMA (30 mg/kg i.p.) induces locomotor activity after the
first injection in WT and 5-HT2B
2/2 mice compared to saline injection
D). The stimulant effect of a challenge dose of MDMA (30 mg/kg) was
significantly enhanced compared to the first injection in both WT and
5-HT2B
2/2 mice D). Data (means6SEM, n=8214 per group) were
analyzed by two-way ANOVA with genotype (A–D) or RS127445 pre-
treatment (B–C) and MDMA treatment as main factors. A significant
interaction was observed for the locomotor activity in figure A)
F (2,66)=12.86 p,0.01, and B) F (2,54)=11.49 p,0.01, as well as a main
effect of genotype F (2, 66)=15.68, p,0.001 (A) or RS127445 pre-
treatment F (2, 54)=10.24, p,0.05 (B) and of MDMA treatment
F (1,66)=9.26, p,0.001 (A), and F (1,54)=17.04, p,0.001 (B). No
significant interaction was observed for the locomotor activity in figure
C) F (2,66)=3.57, ns, whereas a main effect of RS127445 pre-treatment
at the 1
st MDMA injection, F (2,66)=28.56, p,0.001, and of MDMA
treatment F (1,66)=6.64, p,0.01 were detected. Neither a significant
interaction, F (2,50)=0.25, ns, nor a main effect of genotype F
(1,50)=0.9, ns, was observed for the locomotor activity in figure D),
whereas a main effect of MDMA treatment, F (2,50)=82.72, p,0.001,
was detected. Bonferroni tests were used for post-hoc comparisons. The
null hypothesis was rejected at the p,0.05 level; *p,0.05; **p,0.01;
***p,0.001 compared to saline-treated mice. up,0.05; uuup,0.001
compared to MDMA 1
st injection. Locomotor sensitization after
repeated MDMA injection in WT and 5-HT2B
2/2 mice (E): MDMA
(10 mg/kg i.p.) increases locomotor activity after the first injection (day
1; d1) in WT mice but not in 5-HT2B
2/2 mice compare to saline injection.
Repeated MDMA injection during the following days (Day 2 to 5, d2–d5)
increases locomotor activity only in WT mice. The stimulant effect of a
challenge dose of MDMA (10 mg/kg) 5 days later (day 10; d10) was
significantly enhanced compared to the first injection in WT mice, while
it had no effect in 5-HT2B
2/2 mice. Data (means6SEM, n=8 per group)
were analyzed by two-way ANOVA with genotype and MDMA
treatment as main factors. Bonferroni tests were used for post-hoc
comparisons. The null hypothesis was rejected at the p,0.05 level;
**p,0.01; ***p,0.001 compared to saline-treated mice. uuup,0.001
compared to MDMA day 1 injection.
doi:10.1371/journal.pone.0007952.g001
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anesthetized with pentobarbital (30 mg/kg, i.p.; Sanofi-Aventis)
and perfused transcardially with 4% (w/v) paraformaldehyde in
0.1 M sodium phosphate buffer, pH 7.5. Brains were postfixed
overnight in the same solution and stored at 4uC. Thirty-
micrometer-thick sections were cut with a Vibratome (Leica) and
stored at –20uC in a solution containing 30% (v/v) ethylene glycol,
30% (v/v) glycerol, and 0.1 M sodium phosphate buffer, until they
were processed for immunofluorescence. Brain regions were
identified using a mouse brain atlas and sections equivalent to
1.54 mm from Bregma were taken. Sections were processed as
previously described [23].
Immunofluorescence Analysis
Confocal microscopy and image analysis were performed at the
Institut du Fer a ` Moulin Imaging Facility. Double- and triple-
labeled images from each region of interest were obtained
bilaterally using sequential laser-scanning confocal microscopy
(SP2; Leica). Neuronal quantification was performed in
3756375 mm images by counting nuclear EGFP fluorescence
(for assessment of D2R-positive cells) and nuclear/cytoplasm Cy3
immunofluorescence (for each marker analyzed). Cell counts were
performed by an observer unaware of the treatment received by
the mice.
Reagents
MDMA (Sigma-Aldrich, Saint-Quentin Fallavier, France) and 2-
amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (RS127445)
[24] (Tocris Bioscience, USA) were slowly dissolved in 0.9%
(wt/vol) NaCl solution (saline). All drugs were administered i.p
(0.1 ml/10 g body weight). RS-127445 was found to have sub-
nanomolar affinity for the 5-HT2B receptor (pKi=9.560.1) and at
least 1,000 fold selectivity for this receptor as compared to
numerous other receptors and monoamine uptake sites [24]. The
acute pharmacological inhibition and genetic deletion of the 5-
HT2B receptor gives rise to an identical phenotype vis-a `-vis
MDMA-induced behavioral effect. Based on the initial study
showing that RS127445 completely (1; 0.5 and 0.1 mg/kg; i.p) or
partially (0.05 mg/kg) blocked MDMA-induced locomotion in
WT mice and had no effect on basal locomotor activity [19] we
used the 0.5 mg/kg dose (i.p).
Statistics
Microdialysis data were analyzed by two-way ANOVA
repeated measures with drug treatment and time as factors.
Behavioral and biochemical assays were analyzed by two-way
analysis of variance (ANOVA) with treatment and genotype as
main factors. Bonferroni or Dunnett test were used for post hoc
comparisons depending on the experiment. P,0.05 was prede-
termined as the threshold for statistical significance.
Results
Effect of 5-HT2B Receptor Inhibition on Behavioral
Sensitization to Repeated MDMA Injection
Behavioral sensitization corresponds to a progressive enhance-
ment of locomotor responses following repeated exposure to drug
abuse [25]. Once established, sensitization is long-lasting since it is
observed after re-exposure to the drug several weeks later [26,27].
Locomotor sensitization is thought to underlie important aspects of
vulnerability to drug addiction [28]. Since MDMA binds to DAT
with a lower affinity than SERT [29] it may differentially affect
these transporters, at low (10 mg/kg) or high (30 mg/kg) doses.
We thus measured locomotor activity and behavioral sensitization
in response to low (10 mg/kg) and high doses (30 mg/kg) of
MDMA in WT, 5-HT2B
2/2 or RS127445-treated wildtype mice
(Figure 1). Figure 1A shows that acute injection (1
st injection) of
MDMA (10 mg/kg) increases locomotor activity compared to
saline injection in WT mice. The stimulant effect of a challenge
dose of MDMA (10 mg/kg) seven days later (2
nd injection) was
significantly enhanced compared to the first injection in WT mice.
However, neither the first nor the second injection induced
locomotion in 5-HT2B
2/2 mice (Figure 1A) or RS127445-treated
mice (Figure 1B) compared to saline injection. In the same way,
locomotor sensitization induced with a repeated injection
paradigm (i.e. daily injection of MDMA 10 mg/kg during 5 days)
was also abolished in 5-HT2B
2/2 compared to WT mice (Fig. 1E).
To evaluate the role of 5-HT2B receptors in the locomotor
sensitization induction, WT mice were treated with a selective 5-
HT2B receptor antagonist (RS127445; 0.5 mg/kg) 30 min before
the first injection of MDMA. The challenge injection of MDMA
was then performed in absence of RS127445; the increased
responsiveness to the challenge injection (2
nd) of MDMA was thus
totally abolished, supporting a role for the 5-HT2B receptor in the
induction of sensitization (Figure 1C).
By contrast, in both WT and 5-HT2B
2/2 mice, a high dose of
MDMA (30 mg/kg) induced a 30-fold increase in locomotion and
a significant increase in locomotor sensitization (Figure 1D). These
experiments indicate that, unlike low doses, high doses of MDMA
induce a 5-HT2B receptor-independent sensitization in mice.
Effect of 5-HT2B Receptor Inhibition on MDMA (30 mg/
kg)-Evoked Increase in 5-HT and DA Level in NAcc as
Measured by In Vivo Microdialysis
We have previously shown that MDMA (10 mg/kg)-induced
hyperlocomotion, 5-HT and DA release are abolish in 5-HT2B
2/2
or RS127445 treated mice [19]. In order to understand the
contrasting behavioral results observed between low (10 mg/kg)
and high (30 mg/kg) doses of MDMA, we compared changes in
accumbal 5-HT and DA extracellular concentrations in awake
WT, 5-HT2B
2/2 and RS127445-treated mice (Figure 2). In WT
mice, MDMA (30 mg/kg) induced a 160-fold increase in
extracellular 5-HT levels in the NAcc within 80 minutes
(Figure 2A), an effect that was absent in RS127445-treated or 5-
HT2B
2/2 mice (Figure 2A and 2C respectively). However,
MDMA (30 mg/kg) caused a 100-fold increase in extracellular
DA concentration in the NAcc of wild type mice within 50 minutes
(Figure 2B); in 5-HT2B
2/2 or RS127445-treated mice, MDMA
elicited a 50-fold increase in synaptic DA levels in the NAcc within
30 minutes (Figure 2B and 2D respectively). Basal 5-HT and DA
extracellular level are reported in Figure 2E and 2F respectively
for WT and 5-HT2B
2/2 mice. Therefore, the dependence of
MDMA-induced 5-HT release on 5-HT2B receptors persists even
at a high dose (30 mg/kg) of MDMA; the remaining MDMA-
induced DA release, however, appears to be partially independent
of 5-HT2B receptors and may explain the hyperlocomotion and
locomotor sensitization seen in 5-HT2B
2/2 mice that are not
observed at 10 mg/kg of MDMA.
Effect of 5-HT2B Receptor Inhibition on MDMA-Induced
CPP and CPP Reinstatement
In order to evaluate the role of 5-HT2B receptors in the
reinforcing effects of MDMA, we compared WT and 5-HT2B
2/2
mice in the CPP paradigm. CPP is a robust model used to assess
the addictive properties of drugs of abuse [22]. This procedure is
based on the fact that the pairing of neutral distinctive
environmental stimuli with a drug results in an acquired
5-HT2BR in Ecstasy Reward
PLoS ONE | www.plosone.org 4 November 2009 | Volume 4 | Issue 11 | e7952Figure 2. Effect of 5-HT2B receptor inhibition on MDMA (30 mg/kg) - evoked increase in NAcc 5-HT and DA levels as measured by in
vivo microdialysis in awake mice. Effect of MDMA (30 mg/kg i.p.) or saline injection on (A) 5-HT, (B) DA concentrations in dialysates from the
NAcc of WT or RS127445 (0.5 mg/kg i.p.)-WT pre-treated mice. Effect of 5-HT2B receptor genetic ablation on MDMA (30 mg/kg)-induced changes in
(C) 5-HT or (D) DA levels in NAcc. MDMA or saline solutions were injected 35 minutes after test began (arrow). Basal 5-HT and DA extracellular levels
are reported at lower scale in E) and F) respectively for WT and 5-HT2B-/- mice. Data (means6SEM, n=425 per group) were analyzed by two-way
ANOVA (repeated measures) with RS-administration or genotype and time as main factors. A significant interaction was observed after 5-HT2B
receptor pharmacological inhibition (RS127445) (A–B) for 5-HT levels F (36,180)=429.5 p,0.001 as well as for DA levels F (36,180)=82.43, p,0.001. A
main effect of RS-treatment was observed for 5-HT levels F (2, 180)=3677, p,0.001 and for DA levels F (2, 180)=449.7, p,0.001, whereas a main
effect of time was also detected for 5-HT levels F (18, 180)=498.1, p,0.001 and for DA levels F (18, 180)=166.5, p,0.001. For 5-HT2B-/- mice (C–D), a
significant interaction was not observed for 5-HT levels F (18,126)=1.33, ns, but it was the case for DA levels F (18,126)=53.98, p,0.001. Neither a
main effect of genotype F (1, 126)=0.36, ns, nor of time F (18, 126)=1.08, ns, was observed for 5-HT levels. On the contrary, a main effect of genotype
F (1, 126)=363.3, p,0.001, as well as of time F (18, 126)=53.55, p,0.001 was detected for DA levels. Bonferroni tests were used for post-hoc
comparisons. The null hypothesis was rejected at the p,0.05 level; *p,0.001.
doi:10.1371/journal.pone.0007952.g002
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repeated injection of MDMA (10 mg/kg) in the paired compart-
ment induces CPP in WT mice compared to saline-injected WT
mice. In contrast, MDMA (10 mg/kg)-induced CPP in WT mice
was not observed in 5-HT2B
2/2 mice. However, as observed for
locomotor sensitization, a high dose of MDMA (30 mg/kg) did
induce CPP in both WT and 5-HT2B
2/2 mice (Figure 3A).
Reinstatement of drug-seeking behavior in animals is relevant to
drug relapse in humans. We employed the CPP paradigm to
investigate the extinction and reinstatement of the place-
conditioned response to MDMA injection, a model that is
consistent with drug-seeking behavior. Figure 2B shows that
MDMA (10 mg/kg) re-exposure induces reinstatement of CPP
after an initial extinction of CPP (12 days) in WT mice. To
evaluate the role of the 5-HT2B receptor in the reinstatement of
CPP, mice expressing CPP extinction were treated with a selective
5-HT2B receptor antagonist (RS127445, 0.5 mg/kg ip) or saline
solution 30 min before MDMA re-exposure. MDMA-induced
reinstatement was completely blocked in RS127445-pretreated
mice, indicating that 5-HT2B receptors are required for the
induction of CPP reinstatement.
Effect of 5-HT2B Receptor Inhibition on MDMA-Induced
ERK Activation
Accumbal ERK stimulation participates in the long-lasting
behavioral effects of drugs of abuse, [30] including CPP induced
by MDMA [31]. This regulation required combined activation of
dopamine and glutamate receptors. Thus, phosphorylation of
ERK provides an index of post-synaptic DA receptor activation
in the NAcc. The absence of DA release in the NAcc after acute
MDMA (10 mg/kg) injection [19] and CPP after MDMA
(10 mg/kg) conditioning indicates that mice lacking functional
5-HT2B receptor should not exhibit ERK activation with low
dose of MDMA. By contrast, DA release in the NAcc after acute
MDMA (30 mg/kg) injection (Fig. 2) and CPP after MDMA
(30 mg/kg) conditioning (Fig. 3) indicates that mice lacking
functional 5-HT2B receptor should exhibit ERK activation with
high dose of MDMA. In order to assess this question, we
quantified phosphorylated-ERK (p-ERK) immunoreactive neu-
rons in the NAcc of WT and 5-HT2B
2/2 mice 24 hours after the
last MDMA (10 or 30 mg/kg) conditioning in the CPP paradigm
(Figure 4A). Basal ERK phosphorylation was determined in WT
or 5-HT2B
2/2 mice that received saline injection during the CPP
paradigm. As shown in Figure 4B, MDMA (10 mg/kg) re-
exposure induced a 10-fold increase in p-ERK immuno-positive
neurons in the NAcc (only in the shell) of WT mice expressing
CPP. Conversely, in 5-HT2B
2/2 mice, which did not express
CPP after MDMA (10 mg/kg) conditioning, no significant
increase of p-ERK immuno-positive neurons in the NAcc was
seen after MDMA injection. However, a high dose of MDMA
(30 mg/kg) induced—as it did in wild type mice— a 12-fold
increase in p-ERK immuno-positive neurons in the NAcc (shell
and core) of 5-HT2B
2/2 mice expressing CPP compared to
saline-injected 5-HT2B
2/2 mice (Figure 4B and 4C).
MDMA-Induced ERK Activation Occurs Only in D1R-
Expressing NAcc Neurons
In order to characterize the population(s) of p-ERK immuno-
positive neurons seen after MDMA (10 or 30 mg/kg) injection, we
subjected drd2-EGFP transgenic mice to the same CPP protocol
described above that responded as WT mice (not shown), and then
counterstained brain section with a DARPP-32 antibody, a marker
of GABAergic medium-size spiny neurons (MSNs). As shown
in Figure 5, ERK phosphorylation occurred exclusively in
DARPP32-expressing neurons, whereas no staining was detected
in D2R (EGFP)-expressing neurons (Figure 5A and 5C). Almost all
D1R-expressing neurons displayed ERK activation after MDMA
injection (Figure 5B).
Figure 3. Effect of 5-HT2B receptor inhibition on MDMA-induced conditioned place preference in mice. A) Repeated i.p. injection of
MDMA 10 mg/kg induced CPP in WT mice compared to saline injection, but this effect was absent in 5-HT2B
2/2 mice. However, repeated injection of
a high dose of MDMA (30 mg/kg) induced CPP in WT as well as in 5-HT2B
2/2 mice. Data (means6SEM, n=8 per group) were analyzed by two-way
ANOVA with genotype and treatment as main factors, revealing a significant interaction, F(2, 41)=3.93, p,0.05, a main effect of treatment F(2,
41)=11.67, p,0,001 but no effect of genotype F(1, 41)=0.27, ns. Bonferroni tests were used for post-hoc comparisons. In all cases, p,0.05 was
considered statistically significant; **p,0.01 compared to saline-treated mice. B) After an initial extinction of the CPP (12 days) in WT mice, MDMA
(10 mg/kg) re-exposure induced reinstatement of CPP. MDMA-induced reinstatement was not observed in RS127445-pretreated mice. Data
(means6SEM, n=10220 per group) were analyzed by one-way ANOVA. Dunnetts tests were used for post-hoc comparisons. The null hypothesis was
rejected at the p,0.05 level; *p,0.05 **p,0.01 compared to saline-treated mice.
doi:10.1371/journal.pone.0007952.g003
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Sensitization is thought to underlie important aspects of
vulnerability to drug addiction [28] and conditioned place
preference (CPP) is a robust model used to assess the addictive
properties of drugs of abuse. We show here that a ‘‘low’’ dose of
MDMA (10 mg/kg) induces locomotor sensitization and CPP only
in wildtype but not in 5-HT2B
2/2 mice. These findings are
consistent with: 1) our microdialysis data, showing that either
pharmacological inhibition or permanent ablation of 5-HT2B
receptors is sufficient to block entirely both 5-HT and DA release
in the NAcc following acute MDMA (10 mg/kg) injection [19], 2)
lack of accumbal ERK activation in 5-HT2B
2/2 mice following
MDMA (10 mg/kg) conditioning (Fig. 4A). Both behavioral
sensitization and CPP following repeated injection of low doses
(10 mg/kg) of MDMA are thus entirely 5-HT2B receptor-
dependent. These data establish that 5-HT2B receptors are critical
for reinforcing effects properties and establishment of long-term
alterations of behavioral responses to repeated exposure to
MDMA.
Several lines of evidence indicate the involvement of the ERK
pathway in long-term effects of drugs of abuse [30]. ERK is
activated in reward-associated brain areas (including NAcc)
through combined stimulation of DA and glutamate receptors
after acute or repeated treatment with psychostimulant drugs [32].
Indeed, a previous study showed that MDMA (9 mg/kg)-induced
locomotion and CPP were blocked by selective inhibitors of ERK
[31]. We show here that a low dose of MDMA (10 mg/kg) induces
ERK activation in WT but not in 5-HT2B
2/2 mice. This is
consistent with the absence of CPP in these mice following
injection of a low dose of MDMA. Moreover, we find more robust
ERK activation in the NAcc shell compared to the core following
MDMA injection. This is in line with previous studies showing
that ERK activation parallels the DA release seen in the shell
compared to the core following MDMA injection [33], supporting
a critical involvement of DA release in the shell for the rewarding
properties of MDMA. Thus, 5-HT2B receptors are critical for the
CPP and ERK phosphorylation observed in mice following
repeated injection of a low dose of MDMA.
In order to characterize the neurons that display increased
p-ERK after MDMA injection, we used a DARPP-32 antibody, a
marker of GABAergic medium-size spiny neurons (MSNs), in drd2-
EGFP transgenic mice subjected to the CPP paradigm. MSNs
account for .95% of the striatal neurons in rodents [34]. MSNs
projecting to the substantia nigra pars reticulata and medial globus
pallidus express mostly DA D1 receptors, whereas MSNs
projecting to the lateral globus pallidus express preferentially DA
D2 receptors [35]. These two subpopulations are homogenously
distributed throughout the striatum, and are known to have
opposite effects on behavior [35,36]. MDMA-induced locomotor
activity, behavioral sensitization [37,38], self-administration [39]
and pERK stimulation [40] have all been shown to be reduced in
D1 receptor antagonist-treated mice. We show here that ERK
phosphorylation, following MDMA injection, occurs exclusively in
DARPP32-expressing neurons, whereas no ERK labeling was
detected in D2 receptor (EGFP)-expressing neurons. A recent
study showed that in this transgenic mouse line, 100% of the
MSNs express either D1 or D2 receptors [41]. Thus, our results
demonstrate that the ERK activation induced by repeated
MDMA injection occurs selectively in D1 receptor-striatonigral
MSNs in the NAcc (shell and core). This complete segregation
between the striatonigral and striatopallidal circuits within the
striatum, in response to MDMA injection, was independently
reported for cocaine [23]. Activated ERK, in turn, induces CREB
Figure 4. Effect of 5-HT2B receptor on MDMA-induced ERK
activation. 24 hours after CPP training (Figure 3), the same WT and
5-HT2B
2/2 mice were re-exposed to saline, MDMA 10 mg/kg or MDMA
30 mg/kg before being processed for immunohistochemistry. A) Single
confocal sections showing p-ERK1/2 immunoreactivity in the NAcc Shell
of WT and 5-HT2B
2/2mice 10 min after re-exposure. Scale bar: 40 mm. B,
C) Quantification of p-ERK1/2 immunoreactive neurons in the NAcc
Shell (B) and NAcc Core (C) of WT and 5-HT2B
2/2 mice 10 min after re-
exposure. Note the strength of ERK activation induced by re-exposure
to both MDMA doses in WT animals. This activation was absent in
5-HT2B
2/2 mice at 10 mg/kg MDMA, although it fully recovered at
30 mg/kg MDMA. Data (means6SEM; n=4210 mice per group) were
analyzed using two-way ANOVA with genotype and treatment as main
factors, revealing a significant interaction in NAcc Shell F(2, 33)=21.27,
p,0,001 and in NAcc Core, F(2, 33)=4.77, p,0.05. A main effect of
treatment was observed in NAcc Shell F(2, 33)=45.29, p,0,001 and in
NAcc Core, F(2, 33)=21.85, p,0,001, but no effect of genotype neither
in NAcc Shell F(1, 33)=0.53, ns nor in NAcc Core, F(1, 33)=0.21, ns.
Bonferroni tests were used for post-hoc comparisons. The null
hypothesis was rejected at the p,0.05 level; ** p,0.01, *** p,0.001
compared to saline-treated mice; uuu p,0.001, compared to MDMA
10 mg/kg treated mice.
doi:10.1371/journal.pone.0007952.g004
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PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e7952Figure 5. MDMA reexposure after CPP induces strong ERK1/2 activation exclusively in striatonigral medium-sized spiny neurons
(MSNs) of the NAcc shell. drd2-EGFP BAC transgenic mice, in which EGFP expression is driven by the D2-receptor promoter, were trained for the
same CPP protocol as in Figure 3 and re-exposed 24 hours after CPP training to saline, MDMA 10 mg/kg or MDMA 30 mg/kg. A) Single confocal
sections showing p-ERK1/2 immunoreactivity (1–3, red) colocalized with D2-mediated EGFP (19–39, green) and DARPP-32 immunoreactivity (10–30,
blue) in the NAcc Shell of drd2-EGFP mice 10 minutes after re-exposure to saline (1–10), MDMA 10 mg/kg (2–20) or MDMA 30 mg/kg (3–30). The
absolute segregation from D2-EGFP neurons in 19–39 and the complete colocalization with a fraction of DARPP-32-positive neurons in 10–30 reveal
the identity of neurons expressing ERK1/2 activation, which are D1 receptor-containing striatonigral MSNs. Scale bar: 40 mm. B) p-ERK1/2 (red) + D2-
EGFP (green) + DARPP-32 (blue) colocalized confocal image of the NAcc shell of an animal challenged with 10 mg/kg MDMA. Arrows point to
neurons labeled only in blue, which are the small fraction of striatonigral MSNs that do not show ERK activation. Scale bar: 40 mm. C) Quantification of
p-ERK1/2 immunoreactive neurons among EGFP-negative (2) or EGFP-positive (+) neurons in the NAcc Shell of drd2-EGFP mice 10 min after saline,
MDMA 10 mg/kg or MDMA 30 mg/kg injections. D) Quantification of p-ERK1/2 immunoreactive neurons among EGFP-negative (2) or EGFP-positive
(+) neurons in the NAcc Core of drd2-EGFP mice 10 min after saline, MDMA 10 mg/kg or MDMA 30 mg/kg injections. Data (means6SEM; n=3 mice
per group) were analyzed using two-way ANOVA with genotype and treatment as main factors, revealing a significant interaction F(2, 12)=16.8,
p,0,001 and a main effect of treatment F(2, 12)=15.93, p,0,001 as well as of genotype F(1, 12)=83.71, p,0.001. Bonferroni tests were used for
post-hoc comparisons. The null hypothesis was rejected at the p,0.05 level; *** p,0.001 compared to saline-treated mice.
doi:10.1371/journal.pone.0007952.g005
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kinase-1 (MSK1) activation and histone H3 phosphorylation, all of
which further regulate gene expression in D1 receptor-expressing
neurons [42,43]. These gene expression changes may contribute to
drug-induced persistent neuroadaptations (i.e., alterations of
dendritic morphology, synaptic transmission and synaptic plastic-
ity) [42–44]. Our work indicates that MDMA induces DA-
dependent ERK activation in D1 receptor-expressing neurons that
likely triggers the same signaling cascade as other drugs of abuse.
Our data show that unlike a ‘‘low’’ dose of MDMA (10 mg/kg),
a high dose (30 mg/kg) induces locomotor sensitization and CPP
in 5-HT2B
2/2 mice. Since MDMA binds to DAT with a lower
affinity than SERT [29] it may, at low (10 mg/kg) or high
(30 mg/kg) doses, mostly bind to and reverse SERT or both
SERT/DAT, respectively. The contrasting behavior observed
between low and high doses in animals provides some evidence
that the dose of MDMA affects its mode of action [45]. These
findings are consistent with our microdialysis data, showing that
either pharmacological inhibition or permanent ablation of 5-
HT2B receptors is sufficient to block entirely 5-HT and DA release
in the NAcc following a ‘‘low’’ dose of MDMA [19] while a ‘‘high’’
dose of MDMA induces DA release without 5-HT release (fig. 2).
These findings support the notion that, according to the dose,
MDMA has different pharmacological targets leading to different
behavioral effects. A low dose of MDMA induce a 5-HT2B
receptor-dependent 5-HT release that most likely promotes
subsequent DA release in NAcc, while a ‘‘high’’ dose activates
also a 5-HT2B receptor-/5-HT-independent DA release, probably
via a direct effect of MDMA on DAT. In this regard, a recent
study showed that, according to the dose, MDMA has a dual effect
(5-HT dependent or independent) on DA neurons firing [46].
Although some literature supports these observations (i.e., the
released 5-HT drives the release of DA), other data showed that
fenfluramine, a selective 5-HT releaser, fails to induce DA release
[47]. This is probably due to the differential 5-HT releasing
capacity of fenfluramine compared to MDMA [48] and the
complexity of the regulation of mesolimbic DA activity by 5-HT
and its receptors (i.e. differences in the affinities of the various 5-
HT receptors for 5-HT, differential effects of 5-HT agonists on
second-messenger systems, different receptor desensitization and
the nature of the 5-HT receptor expressing neurons) {See [49] and
[4] for an extensive discussion}. Alternatively, MDMA and
its N-demethylated metabolite 3,4-methylenedioxyamphetamine
(MDA) each preferentially bind to and activate human recombi-
nant 5-HT2B receptors at concentrations close to those reported in
plasma after a single recreational dose. MDMA and MDA, elicit
also a prolonged mitogenic responses in human valvular interstitial
cells, via direct activation of 5-HT2B receptors [50]. Thus, the
behavioral effect of MDMA may be mediated, in part, through
direct action on postsynaptic 5-HT2B receptors.
That a high dose of MDMA-induced CPP in 5-HT2B
2/2 mice
in a DA-dependent fashion (accumbal ERK activation) suggests
that DA release in NAcc is sufficient for the rewarding properties
of MDMA whatever mode of DA release (i.e with or without a
supportive role of 5-HT). Moreover, the lack of 5-HT release in 5-
HT2B
2/2 or RS127445-treated mice following acute injection of
MDMA (30 mg/kg) suggest that MDMA induces CPP and
stimulates ERK phosphorylation through an entire 5-HT-
independent but DA-dependent mechanism.
The mean recreational dose of MDMA in humans (oral route) is
about 2 mg/kg (70–200 mg of MDMA per pill) [51]. In line with
the principle of interspecies drug dose scaling–also still a matter of
debate– the low dose of MDMA used in mice is most likely a
‘‘high’’ human dose [52]. This supports the notion that
pharmacological blockade of the 5-HT2B receptors in Human
might counteract the effect of MDMA after a recreational dose as
it did in mice. Unlike SSRIs, the 5-HT2B receptor antagonist
RS127445 completely blocks MDMA induced 5-HT and DA
release, in response to low dose of MDMA. Moreover, RS127445
has no effect on basal 5-HT extracellular concentration, unlike
SSRIs which may induce serotonin syndrome due to a synergistic
increase in synaptic serotonin [53]. The fact that reinstatement
after CPP extinction is abolished by RS127445, a selective 5-HT2B
receptor antagonist in WT mice highlights the putative clinical
efficacy of 5-HT2B receptor blockade in the treatment of MDMA
abuse. Antagonists of 5-HT2B receptor could serve as promising
therapeutic drugs for the prevention of the acute and long-term
effects associated with MDMA use, and could be a way to avoid
relapse in abstaining MDMA users. In line with this hypothesis, a
series of atypical antipsychotics (clozapine, amisulpride, metoclo-
pramine, olanzapine and aripiprazole) that have potent 5-HT2B
receptor antagonist properties would be expected to be effective
prophylactics against MDMA abuse [54–56]. Indeed, some
antipsychotics reduces MDMA-stimulated locomotion and hyper-
thermia, effects believed to be mediated at least in part by the 5-
HT2A receptor antagonist properties [6,57,58]. The contribution
of 5-HT2B receptors to the atypical profile of some benzamide
antipsychotic has yet to be investigated, in respect to psychostim-
ulants addictive effects.
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